Novartis and Genentech push for clarity from FDA on how disease progression models can be used for regulatory decisions

As companies continue their search for new drugs for debilitating diseases that progress over years and are notoriously tough to crack (think Alzheimer’s disease), the FDA is igniting a wider conversation on how and when the biopharma industry might be able to use specific models in their development programs.


Click to view original post